Healthpeak Properties (NYSE:DOC) Rating Lowered to “Sell” at Wall Street Zen

Healthpeak Properties (NYSE:DOC) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other research analysts have also recently weighed in on DOC. Argus cut shares of Healthpeak Properties from a “buy” rating to a “hold” rating in a report on Thursday, February 5th. Citigroup reduced their price objective on shares of Healthpeak Properties from $18.00 to $17.50 and set a “neutral” rating on the stock in a report on Wednesday, April 1st. Wells Fargo & Company restated a “positive” rating on shares of Healthpeak Properties in a research report on Tuesday, February 3rd. Morgan Stanley reduced their price objective on shares of Healthpeak Properties from $21.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, April 28th. Finally, Scotiabank upgraded shares of Healthpeak Properties to a “hold” rating in a research report on Thursday, April 23rd. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $18.04.

Healthpeak Properties Price Performance

Shares of DOC stock opened at $16.44 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 2.82 and a quick ratio of 2.82. The firm’s 50-day moving average is $16.94 and its two-hundred day moving average is $17.15. Healthpeak Properties has a 12 month low of $15.70 and a 12 month high of $19.68. The company has a market capitalization of $11.43 billion, a PE ratio of 164.42, a price-to-earnings-growth ratio of 2.27 and a beta of 1.00.

Healthpeak Properties (NYSE:DOC) last issued its earnings results on Monday, February 2nd. The real estate investment trust reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.02. Healthpeak Properties had a net margin of 2.52% and a return on equity of 0.84%. The company had revenue of $719.40 million for the quarter, compared to the consensus estimate of $685.14 million. During the same period in the previous year, the firm earned $0.46 earnings per share. Healthpeak Properties’s quarterly revenue was up 3.1% compared to the same quarter last year. Analysts predict that Healthpeak Properties will post 1.74 earnings per share for the current year.

Institutional Investors Weigh In On Healthpeak Properties

Large investors have recently added to or reduced their stakes in the business. Mather Group LLC. acquired a new stake in Healthpeak Properties in the 3rd quarter valued at about $25,000. City Holding Co. acquired a new stake in shares of Healthpeak Properties in the third quarter worth approximately $26,000. WPG Advisers LLC boosted its position in shares of Healthpeak Properties by 270.2% in the fourth quarter. WPG Advisers LLC now owns 1,640 shares of the real estate investment trust’s stock worth $26,000 after acquiring an additional 1,197 shares during the last quarter. Advocate Investing Services LLC acquired a new stake in shares of Healthpeak Properties in the fourth quarter worth approximately $26,000. Finally, Elyxium Wealth LLC acquired a new stake in shares of Healthpeak Properties in the fourth quarter worth approximately $31,000. 93.57% of the stock is owned by institutional investors and hedge funds.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.